Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Locally Advanced, Unresectable Pancreatic Cancer Treated by Stereotactic Radiation Therapy

국소적으로 진행된, 절제 불가능한 췌장암에서 정위 방사선 치료

  • Choi Chul-Won (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Kim Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Cho Chul-Koo (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Yoo Seong-Yul (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Yang Kwang-Mo (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Yoo Hyung-Jun (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Lee Dong-Han (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Ji Young-Hoon (Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences) ;
  • Han Chul-Ju (Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences) ;
  • Kim Jin (Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences) ;
  • Kim Young-Han (Department of Radiology, Korea Institute of Radiological and Medical Sciences)
  • 최철원 (원자력병원 방사선종양학과) ;
  • 김미숙 (원자력병원 방사선종양학과) ;
  • 조철구 (원자력병원 방사선종양학과) ;
  • 류성렬 (원자력병원 방사선종양학과) ;
  • 양광모 (원자력병원 방사선종양학과) ;
  • 유형준 (원자력병원 방사선종양학과) ;
  • 이동한 (원자력병원 방사선종양학과) ;
  • 지영훈 (원자력병원 방사선종양학과) ;
  • 한철주 (원자력병원 내과) ;
  • 김진 (원자력병원 내과) ;
  • 김영한 (원자력병원 방사선과)
  • Published : 2006.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Puroose: In order to find out whether stereotactic radiation therapy (RT) using CyberKnife (CK) could improve survival rate and lower acute toxicity compared to conventional RT. Materials and Methods: From April 2003 through April 2004, 19 patients with Eastern Cooperative Oncology Group (ECOG) performance status ${\leq}3$ and locally advanced pancreas cancer without distant metastasis, evaluated by CT or PET/CT, were included. We administered stereotactic RT consisting of either 33 Gy, 36 Gy or 39 Gy in 3 fractions to 6, 4 and 9 patients, respectively, in an effort to increase the radiation dose step by step, and analyzed the survival rate and gastrointestinal toxicities by the acute radiation morbidity criteria of Radiation Therapeutic Oncology Group (RTOG). Prognostic factors of age, sex, ECOG performance score, chemotherapy, bypass surgery, radiation dose, CA 19-9, planning target volume (PTV), and adjacent organ and vessel invasion on CT scan were evaluated by Log Rank test. Results: The median survival time was 11 months with 1-year survival rate of 36.8%. During follow-up period (range $3{\sim}20$ months, median 10 months), no significant gastrointestinal acute toxicity (RTOG grade 3) was observed. In univariate analysis, age, sex, ECOG performance score, chemotherapy, bypass surgery, radiation dose, CA 19-9 level, and adjacent organ and vessel invasion did not show any significant changes of survival rate, however, patients with PTV (80 cc showed more favorable survival rate than those with PTV>80 cc (p-value<0.05). In multivariate analysis, age younger than 65 years and PTV>80 cc showed better survival rate. Conclusion: In terms of survival, the efficacy of stereotactic radiation therapy using CK was found to be superior or similar to other recent studies achieved with conventional RT with intensive chemotherapy, high dose conformal RT, intraoperative RT (IORT), or intensity modulated RT (IMRT). Furthermore, severe toxicity was not observed. Short treatment time in relation to the short life expectancy gave patients more convenience and, finally, quality of life would be increased. Consequently, this could be regarded as an effective novel treatment modality for locally advanced, unresectable pancreas cancer. PTV would be a helpful prognostic factor for CK.

목적: 국소적으로 진행된, 절제 불가능한 췌장암 치료에 있어 고식적 방사선 치료와 비교하여 Cyberknife(CK)를 이용한 정위 방사선 치료의 생존율 및 급성 독성에 대해 분석하고자 하였다. 대상 및 방법: 2003년 4월부터 2004년 4월까지의, Eastern Cooperative Oncology Group (ECOG) 활동도 3 이하이며 CT 및 PET/CT로 평가하여 원격 전이 없는 국소 진행된 췌장암 환자 19명을 대상으로 하였다 대상 환자는 점차 방사선량을 증가시키는 방법으로 33 Gy, 36 Gy, 39 Gy를 3분할로 각각 6명, 4명, 9명에서 CK를 이용한 정위 방사선 치료를 시행하였으며, 생존율 및 Radiation Therapeutic Oncology Group (RTOG) acute radiation morbidity criteria에 의한 위장관 독성을 분석하였다 또한 나이, 성별, ECOG 수행 점수, 항암 치료, 우회로 조성술(bypass surgery) 여부, 방사선량, CAl9-9, 계획용 표적 체적(planning target volume, PTV), CT상 주위 장기 및 혈관 침범 여부 등을 Log Rank test를 이용하여 예후 인자를 평가하였다. 결과: 본 연구에서 중앙 생존 기간은 11개월, 1년 생존율은 36.8%였다. 추적 조사 기간 중(범위 $3{\sim}20$개월, 중앙값 10개월) 유의한 위장관 급성 독성은 관찰되지 않았다 단일 인자 분석에서 계획용 표적 체적만이 유의한 예후 인자로 80cc 이하인 경우가 80cc 이상인 경우보다 생존율이 높았으며(p-value < 0.05), 나이, 성별, ECOG 수행 점수, 항암 치료, 우회로 조성술, CAl9-9 수치, 주위 장기 및 혈관 침범 여부 등에서는 통계적으로 유의한 차이를 보이지 않았다. 다인자 분석에서는 65세 이하인 경우와 PTV 80 co 이하인 경우에서 생존율이 높았다. 결론: 고식적 방사선 치료, 고선량 입체조형 방사선 치료(high dose conformal radiation therapy), 수술 중 방사선 치료(intraoperative radiation therapy) 또는 세기 조절 방사선 치료(Intensity modulated radiation therapy, IMRT)를 이용한 최근의 결과와 비교하여 CK를 이용한 정위 방사선 치료는 생존율 측면에서 비슷하거나 나은 결과를 보였다. 또한 심각한 부작용은 관찰되지 않았으며 짧은 기간의 치료로 환자에게 편의를 제공할 수 있어 결과적으로 삶의 질을 향상시킬 수 있을 것이다. 따라서, 이 새로운 치료 방법은 국소 진행된, 절제 불가능한 췌장암 환자에서 심각한 부작용 없는 효과적인 치료가 될 것으로 생각된다. 또한 계획용 표적 체적은 CK 치료의 유용한 예후 인자로 사용될 것이다.

Keywords

References

  1. Central Cancer Registry Center Ministry of Health and Welfare, Korea. Annual report of the central cancer registry in Korea 2002
  2. Shankar A, Russell RC. Recent advances in the surgical treatment of pancreatic cancer. World J Gastroenterol 2001; 7:622-626 https://doi.org/10.3748/wjg.v7.i5.622
  3. Lee SJ. Clinical study on pancreatic cancer and its prognostic factors. Korean J Gastoenterol 1994;26: 1010-1020
  4. Whang YW, Chang HJ, Lee JK, et al. Survival and recurrence pattern after curative resection of pancreatic cancer. Korean J Gastoenterol 2001 ;38:276-283
  5. Ghaneh P, Slavin J, Sutton R, et al. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2001;7:482-489 https://doi.org/10.3748/wjg.v7.i4.482
  6. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;53: 146-150 https://doi.org/10.1016/S0360-3016(01)02806-1
  7. Fisher BJ, Perera FE, Kocha W, et al. Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1999;45:291-295
  8. Kornek GV, Potter R, Selzer E, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. Int J Radiat Oncol Biol Phys 2001; 49:291-295 https://doi.org/10.1016/S0360-3016(00)00773-2
  9. Andre T, Balosso J, Louvet C, et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 2000;46: 903-911 https://doi.org/10.1016/S0360-3016(99)00478-2
  10. Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (1MRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;59:454-459 https://doi.org/10.1016/j.ijrobp.2003.11.019
  11. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for respectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997;39:39-49 https://doi.org/10.1016/S0360-3016(97)00295-2
  12. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017-1021 https://doi.org/10.1016/j.ijrobp.2003.11.004
  13. Kim JG, Lee DH, Kim MS, et al. A study of the reduction of organ motion from respiration. Korea J Medi Phy 2004;15:179-186
  14. Mortel GG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads+5-fluorourcil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710 https://doi.org/10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4
  15. Klaassen DJ, Maclntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1985;3:373-378 https://doi.org/10.1200/JCO.1985.3.3.373
  16. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy(chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-755 https://doi.org/10.1093/jnci/80.10.751
  17. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-Fluorouracil for locally unresectable pancreatic carcinoma. Ann Surgery 1979;189-205
  18. Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous flourouracil infusion with radiotherapy in the management of localized pancreaticobiliary carcinoma: 1 phase Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:227-232 https://doi.org/10.1200/JCO.1995.13.1.227
  19. Treurniet-Donker AD, Van Mielro MJM, Van Putten WLJ, et al. Localized unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1990;18:560-562
  20. Ishii H, Okada S, Tokuuye. et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-1520 https://doi.org/10.1002/(SICI)1097-0142(19970415)79:8<1516::AID-CNCR11>3.0.CO;2-0
  21. Okusaka T, Okada S, Tokuuye K, et al. Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer 2001;91:1384-1389 https://doi.org/10.1002/1097-0142(20010401)91:7<1384::AID-CNCR1142>3.0.CO;2-4
  22. Safran H, Moore T, lannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001;49:1275-1279 https://doi.org/10.1016/S0360-3016(00)01527-3
  23. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9-18 https://doi.org/10.1385/IJGC:29:1:09
  24. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;54:137-141
  25. Kim YB, Seong JS, Song SY, et al. Concurrent chemoradiotherapy for unresectable pancreatic cancer. J Korean Soc Ther Radiol Oncol 2002;20:328-333
  26. Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000;35:81-87
  27. Kamthan AG, Morris JC, Dalton J, et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997;15:2920-2927 https://doi.org/10.1200/JCO.1997.15.8.2920
  28. Martin JL. Harvey HA. Lipton A, et al. Combined chemoradiotherapy for unresectable pancreatic cancer. Am J Clin Oncol 1999;22:309-314 https://doi.org/10.1097/00000421-199906000-00021
  29. Morganti AG, Valentini V, Macchia G, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys 2004;59: 1454-1460 https://doi.org/10.1016/j.ijrobp.2004.01.035
  30. Talamonti MS, Catalano PJ. Vaughn DJ, et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 2000;135:81-87
  31. Bai YR. Wu GH, Guo WJ, et al. Intensity modulated radiation therapy and chemotherapy for locally adcanced pancreatic cancer: results of feasibility study. World J Gastreenterol 2003;9:2561-2564 https://doi.org/10.3748/wjg.v9.i11.2561
  32. Song DY. Blomgren H. Stereotactic body radiation therapy for lung tumors. In: Kavanagh BD, Timmerman RD, eds. Stereotactic body radiation therapy. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2005:99-107
  33. Schetter TE, Cardenes HR, Kavanagh BD. Stereotactic body radiation therapy for liver tumors. In: Kavanagh BD, Timmerman RD, eds. Stereotactic body radiation therapy. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2005;115-124
  34. Fowler JF, Tome WA, Welsh JS. Estimation of required doses in stereotactic body radiation therapy. In: Kavanagh BD, Timmerman RD, eds. Stereotactic Body Radiation Therapy. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2005:7-14